Doug Brunk is a San Diego-based award-winning reporter who began covering health care in 1991. Before joining the company, he wrote for the health sciences division of Columbia University and was an associate editor at Contemporary Long Term Care magazine when it won a Jesse H. Neal Award. His work has been syndicated by the Los Angeles Times and he is the author of two books related to the University of Kentucky Wildcats men's basketball program. Doug has a master’s degree in magazine journalism from the S.I. Newhouse School of Public Communications at Syracuse University. Follow him on Twitter @dougbrunk.
News
Pilot Study Finds Experimental CBD Cream Decreases UVA Skin Damage
Histology showed that CBD-treated skin demonstrated reduced UVA-induced epidermal hyperplasia compared with control-treated skin.
News
Topical Ruxolitinib: Analysis Finds Repigmentation Rates in Adolescents with Vitiligo
“Ruxolitinib cream can effectively and safely help many patients repigment, including adolescents,” David Rosmarin, MD, said.
News
More Illnesses Possible Related Linked to Counterfeit Botulinum Toxin Reported
This report follows a CDC advisory published in April 2024 of at least 22 people from 11 states who reported serious reactions after receiving...
News
Topical PDE4 Inhibitor Now Approved for Atopic Dermatitis in Children, Adults
Among children and adults who participated in the INTEGUMENT studies for 28 and 56 weeks, 61.3% and 65.7% saw a 75% reduction in their Eczema Area...
News
Cosmetic Botulinum Toxin A Doses May Differ in Sunny Climates
“Functional musculature differences may arise from chronic behavioral adjustment to high sun exposure levels, requiring greater doses,” the study...
News
Survey Highlights Real-World Use of Upadacitinib in Adults With Atopic Dermatitis
Nearly all experienced improvements in itch, with 86.8% reporting “very much” or “much” improved itch.
News
Small Melanoma In Situ: Single Center Study Finds Recurrence Low With 5-mm Margin Excisions
“This study demonstrated a comparable 0.9% recurrence rate achieved with a conservative 5-mm excisional margin,” the authors reported.
News
Study Addresses Litigation Related to Cutaneous Energy-based Based Device Treatments
Complications from energy-based devices included burns, scarring, and pigmentation changes.
News
FDA Approves Topical Anticholinergic for Axillary Hyperhidrosis
Approval was based on results from two phase 3 studies that enrolled 710 patients with primary axillary hyperhidrosis.
News
Study Finds Major CV Event Risk in Patients With AD Similar to Controls
An unexpected result was that among patients with moderate to severe AD, the risk for MACE was not significantly different from that of non-AD...
News
Atopic Dermatitis: Study Compares Prevalence by Gender, Age, and Ethnic Background
“Results are important for us to consider targeted strategies to address AD burden,” said Raj Chovatiya, MD, PhD....
News
Topical Ruxolitinib Effective for AD in Study of Children Ages 2-11 years
No treatment-related interruptions, discontinuations, or serious adverse events were observed between baseline and week 52.
News
VEXAS Syndrome: Study Highlights Cutaneous Symptoms
Affected individuals exhibit a wide range of manifestations, including cytopenia/myelodysplasia, multiorgan systemic inflammation, and cutaneous...
News
Study Highlights Melanoma Survival Disparities in Rural vs Urban Settings
To characterize the rural population diagnosed with melanoma and assess associated disparities in the United States, researchers used data from...
News
Features of Merkel Cell in Hispanic Patients Explored
The incidence of Merkel cell carcinoma is increasing among all racial groups, especially in the Hispanic population.